Outcome of Weekly Carboplatin–Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum–Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review-Reference-Cited by-同舟云学术

Outcome of Weekly Carboplatin–Paclitaxel-based Definitive Chemoradiation in Oesophageal Cancer in Patients Not Considered to be Suitable for Platinum–Fluoropyrimidine-based Treatment: A Multicentre, Retrospective Review

Published:2020-02 Issue:2 Volume:32 Page:121-130
ISSN:0936-6555
Container-title:Clinical Oncology
language:en
Short-container-title:Clinical Oncology

Author:

Owens R.,Cox C.,Gomberg S.,Pan S.,Radhakrishna G.,Parikh S.,Goody R.,Hingorani M.,Prince S.,Bird T.,Dorey N.,Macgregor U.,Al-Chamali H.,Hurt C.,Mukherjee S.

Funder

Cardiff University

National Institute for Health Research

Biomedical Research Centre

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology

Reference18 articles.

1. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group;Cooper;JAMA,1999

2. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial;Crosby;Lancet Oncol,2013

3. A comparison of carboplatin and paclitaxel with cisplatinum and 5-fluorouracil in definitive chemoradiation in esophageal cancer patients;Honing;Ann Oncol,2014